Russia’s Corona vaccine create enough antibody

By Admin

Russia’s Sputnik V vaccine success in producing antibodies in an early trial of the corona.

The trial report of this ticker published in the famous science magazine ‘The Lancet’ says at least that.

Russia wants to show its ability in the rat race to make vaccines without heeding any rules and regulations this is the notoriety of Russia.

A group of experts thinks that the report published in The Lancet is very wrong.

The vaccine was developed in collaboration with the Russian Ministry of Defense and the RDIF (Russian Direct Investment Fund) at the Gamalia Scientific Research Institute of Epidemiology and Microbiology.

Russia Sputnik V vaccine make antibody to protect corona.

The vaccine is named after Russia’s first artificial satellite, Sputnik V.

Sources in The Lancet say that the six volunteers who were vaccinated in June-July have met with the expected results.

The vaccine is able to provide 100 percent protection against corona without any side effects.

Read More – PUBG out FAUG In: The Indian Game Patron Akshay Kumar

Russia announced on August 12 that it would resist a two-dose Sputnik V corona before embarking on a large-scale trial.

Several international organizations, such as the World Health Organization, have ridiculed Russia’s move.

Their bloodshot eyes froze at the Lancet report.

Within 160 days of vaccination, the 7 volunteers will be placed under the fire of medical science. See how they are.

Sources in the Lancet say they are working on a two-dose vaccine for 42 days.

This is exactly how COVID produces antibodies in the body of an infected person.

However, in the case of COVID, a third-stage randomized trial will show how well the vaccine is able to produce antibodies as well as T-cell immunity which have been vaccinated by AstraZeneca and Oxford.

Hopefully, a senior government official in Moscow told the media that the Lancet report was the answer to questions about the effectiveness and safety of the vaccine.

Sputnik V is being applied to 40,000 volunteers from multiple continents since the first phase of the trial on June 7.

Share This Article
Leave a comment